A recent phase II clinical trial results suggest that the monoclonal antibody hu14.18K322A could help change treatment of children with high-risk neuroblastoma.
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/12/211206215947.htm
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/12/211206215947.htm
Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients
![Chemoimmunotherapy dramatically improved survival of high-risk neuroblastoma patients]()
Reviewed by Anonymous
on
December 08, 2021
Rating:
No comments:
Post a Comment